Pharming announces change in composition of Board Of Supervisory Directors

• Press Release
• Source: Pharming Group N.V.
• On 2:00 am EST, Monday December 1, 2008

LEIDEN, NETHERLANDS--(MARKET WIRE)--Dec 1, 2008 --
Leiden, The Netherlands, December 1, 2008. Biotech company Pharming Group NV ("Pharming" or "The Company") (Euronext: PHARM) announced today that Prof. Dr. B.P.Th. Veltman has notified the Company that he will retire from the Board of Supervisory Directors ("BOSD") effective December 1, 2008. Reaching the age of 76, Dr. Veltman had already previously announced that he had plans to retire from the BOSD at the Annual General Meeting in 2009. Personal circumstances have led him to take this decision at this moment.

Related Quotes Symbol Price Change PHARM.AS 0.52 -0.01 {"s" : "pharm.as,phguf.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Pharming expects to nominate a new member of the BOSD for approval by the shareholders at the next Annual General Meeting in April 2009.

Mr Jaap Blaak, Chairman of Pharming's Board of Supervisory Directors said: "Pharming is very grateful to Dr. Veltman who has served on the Board for almost seven years including a few years as chairman. His extensive knowledge and experience in the Academic world as well as in several high-tech companies has been very important for Pharming's development over the last seven years. Dr. Veltman made many valuable contributions during this period. We regret, but understand and accept, his wish to retire at this moment."

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact:

 
Carina Hamaker, Investor Voice, T: +31 (0)6 537 499 59 or T: +31
(0)71 52 47 400
Julia Phillips (UK), Financial Dynamics, T: +44 (0)20 7269 7187 or T:
+44 (0)7770 827 263
Samir Singh (US), Pharming Group NV, T: +1 908 720 6224
Rein Strijker, Pharming Group NV, T: +31 (0)71 52 47 400

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2008. All rights reserved.